Pharmacology of Drugs for Alzheimer’s Disease

Introduction/Overview

Alzheimer’s disease represents the most prevalent form of dementia, characterized by progressive neurodegeneration leading to cognitive decline, functional impairment, and behavioral disturbances. The pharmacological management of this condition is centered on symptomatic treatment, with emerging therapies targeting underlying disease pathology. The clinical relevance of these agents is substantial, as they aim to modify the disease course, alleviate symptoms, and improve quality of life for patients and caregivers. The complexity of Alzheimer’s pathogenesis, involving cholinergic deficit, glutamatergic excitotoxicity, amyloid-beta plaque deposition, and tau neurofibrillary tangle formation, necessitates a multifaceted pharmacological approach. Current therapeutic strategies are primarily palliative, though recent advances have introduced agents with potential disease-modifying properties.

Learning Objectives

• Classify the primary pharmacological agents used in the treatment of Alzheimer’s disease based on their mechanism of action.
• Explain the molecular and cellular mechanisms of action for cholinesterase inhibitors and NMDA receptor antagonists.
• Compare and contrast the pharmacokinetic profiles, therapeutic applications, and major adverse effect profiles of approved Alzheimer’s medications.
• Identify significant drug-drug interactions and special population considerations relevant to the use of these agents.
• Describe the mechanistic basis and clinical role of emerging disease-modifying therapies targeting amyloid-beta.

Classification

Drugs for Alzheimer’s disease are classified primarily according to their pharmacological mechanism. This classification system aligns with their clinical use and therapeutic targets within the disease’s pathological framework.

Established Symptomatic Drug Classes

• Cholinesterase Inhibitors (ChEIs): This class constitutes first-line symptomatic therapy. Agents include donepezil, rivastigmine, and galantamine. They are further categorized based on their selectivity for acetylcholinesterase versus butyrylcholinesterase and their chemical structure (piperidine, carbamate, phenanthrene alkaloid derivatives).
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine is the sole representative in this class. It is a non-competitive, voltage-dependent antagonist with moderate affinity.

Emerging Disease-Modifying Therapies

• Monoclonal Antibodies Targeting Amyloid-beta (Aβ): This class includes aducanumab, lecanemab, and donanemab. These are immunoglobulin G1 (IgG1) monoclonal antibodies designed to promote clearance of amyloid plaques from the brain.
• Other Investigational Agents: Various classes under investigation include tau aggregation inhibitors, secretase modulators, anti-inflammatory agents, and neurotrophic factors, though these are not yet part of standard pharmacotherapy.

Mechanism of Action

The mechanisms of action for Alzheimer’s drugs are founded on the predominant pathophysiological hypotheses: the cholinergic hypothesis, the glutamatergic hypothesis, and the amyloid cascade hypothesis.

Pharmacodynamics of Cholinesterase Inhibitors

Cholinesterase inhibitors exert their primary effect by reversibly inhibiting the enzyme acetylcholinesterase (AChE) at synaptic clefts in the central nervous system. This inhibition reduces the hydrolysis of the neurotransmitter acetylcholine (ACh), thereby increasing its concentration and duration of action at muscarinic and nicotinic cholinergic receptors. The resultant enhancement of cholinergic neurotransmission is believed to partially compensate for the profound loss of cholinergic neurons originating from the nucleus basalis of Meynert, a hallmark of Alzheimer’s pathology.

Differences exist among agents within this class. Donepezil is a highly selective, reversible inhibitor of AChE. Rivastigmine is a pseudo-irreversible carbamate inhibitor of both AChE and butyrylcholinesterase (BuChE), forming a covalently bound complex that temporarily inactivates the enzyme. Galantamine is a competitive, reversible AChE inhibitor that also acts as an allosteric potentiator of neuronal nicotinic acetylcholine receptors, which may confer additional benefits on attention and neuronal plasticity.

Pharmacodynamics of NMDA Receptor Antagonists

Memantine modulates glutamatergic transmission by antagonizing NMDA-type glutamate receptors. Excessive activation of these receptors by glutamate, particularly under pathological conditions, leads to calcium influx and subsequent excitotoxicity, contributing to neuronal dysfunction and death. Memantine binds preferentially to the NMDA receptor-operated cation channel when it is open during prolonged activation, such as that occurring in Alzheimer’s disease. Its key characteristics are its voltage-dependency and moderate affinity. These properties allow memantine to block pathological, tonic receptor activation associated with excitotoxicity while permitting physiological, phasic activation required for normal synaptic transmission and learning. This mechanism is thought to stabilize neuronal calcium homeostasis and confer neuroprotective effects.

Mechanism of Amyloid-Targeting Monoclonal Antibodies

Monoclonal antibodies like aducanumab, lecanemab, and donanemab are designed to target specific forms or aggregates of the amyloid-beta peptide. Aducanumab and lecanemab selectively bind to aggregated forms of Aβ, including soluble oligomers and insoluble fibrils that constitute amyloid plaques. Donanemab is notable for binding specifically to a pyroglutamated form of Aβ (N3pG-Aβ) that is a major constituent of established plaques. By binding to these pathological species, the antibodies facilitate their clearance from the brain via engagement with the immune system, primarily through microglial-mediated phagocytosis. This reduction in amyloid plaque burden is hypothesized to slow downstream neurodegenerative processes, potentially altering the clinical progression of the disease.

Pharmacokinetics

The pharmacokinetic properties of Alzheimer’s medications significantly influence their dosing regimens, side effect profiles, and utility in special populations.

Absorption and Distribution

All cholinesterase inhibitors are well absorbed orally, though their bioavailability and interaction with food vary. Donepezil has nearly complete oral bioavailability and is unaffected by meals. Rivastigmine has approximately 40% bioavailability but undergoes extensive first-pass metabolism; its absorption is delayed by high-fat food. The rivastigmine transdermal patch provides continuous delivery, bypassing first-pass metabolism and reducing peak-trough fluctuations. Galantamine has high bioavailability and linear kinetics. These agents are widely distributed, with donepezil and galantamine crossing the blood-brain barrier effectively due to their lipophilicity. Memantine is also completely absorbed orally, has linear pharmacokinetics, and readily crosses the blood-brain barrier, with a volume of distribution indicating extensive tissue binding.

The monoclonal antibodies are administered via intravenous infusion. Their large molecular size restricts distribution primarily to the plasma and extracellular fluid, with a slow, active transport process facilitating entry into the central nervous system.

Metabolism and Excretion

The metabolic pathways for these agents are diverse. Donepezil is extensively metabolized by hepatic cytochrome P450 enzymes, primarily CYP2D6 and CYP3A4, followed by glucuronidation. Its metabolites are largely inactive. Rivastigmine is metabolized primarily at its site of action via cholinesterase-mediated hydrolysis, with minimal hepatic CYP involvement. Galantamine undergoes hepatic metabolism partly by CYP2D6 and CYP3A4, with renal excretion of unchanged drug and metabolites. Memantine undergoes minimal hepatic metabolism, with approximately 80% of the administered dose excreted unchanged in urine via tubular secretion.

Monoclonal antibodies are not metabolized by hepatic cytochrome P450 systems. They are degraded into small peptides and amino acids via catabolic pathways throughout the body, similar to endogenous immunoglobulins. Elimination occurs primarily through intracellular proteolytic degradation following fluid-phase or receptor-mediated endocytosis.

Half-life and Dosing Considerations

The elimination half-life is a critical determinant of dosing frequency. Donepezil has a long half-life of approximately 70 hours, permitting once-daily dosing. Rivastigmine, when administered orally, has a short half-life of 1-2 hours, necessitating twice-daily administration; the transdermal patch provides sustained delivery over 24 hours. Galantamine has a half-life of about 7 hours, also requiring twice-daily dosing, though extended-release capsules allow for once-daily administration. Memantine has a terminal half-life of 60-80 hours, supporting once-daily dosing after titration.

The monoclonal antibodies have prolonged half-lives consistent with IgG1 antibodies, ranging from approximately 10 to 28 days, which supports dosing intervals of every two to four weeks. Dosing of all Alzheimer’s medications typically follows a “start low, go slow” titration strategy to improve tolerability by minimizing cholinergic or other adverse effects at treatment initiation.

Therapeutic Uses/Clinical Applications

The clinical application of these agents is guided by disease stage, symptom profile, tolerability, and, increasingly, biomarker status.

Approved Indications

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for the treatment of mild to moderate Alzheimer’s disease. Donepezil also carries an indication for severe Alzheimer’s disease. These agents demonstrate modest but statistically significant benefits on cognitive scales (e.g., ADAS-Cog), activities of daily living, and global clinical impression. The magnitude of effect is generally considered clinically meaningful, though it does not halt disease progression. Memantine is indicated for moderate to severe Alzheimer’s disease. It shows benefit in cognitive function, activities of daily living, and behavioral symptoms. Memantine is often used in combination with a cholinesterase inhibitor in moderate to severe disease, with evidence suggesting additive symptomatic benefits.

The monoclonal antibodies aducanumab, lecanemab, and donanemab are approved under accelerated or traditional pathways for the treatment of early Alzheimer’s disease (mild cognitive impairment or mild dementia stage) with confirmed amyloid pathology. Their use is predicated on the demonstration of amyloid plaque reduction and a modest slowing of clinical decline measured by composite scales integrating cognition and function.

Off-Label and Other Clinical Uses

Cholinesterase inhibitors and memantine are frequently used off-label for other forms of dementia, including vascular dementia, dementia with Lewy bodies, and Parkinson’s disease dementia, with varying levels of supporting evidence. Rivastigmine is formally approved for dementia associated with Parkinson’s disease. In clinical practice, these agents may also be utilized to manage behavioral and psychological symptoms of dementia, such as apathy, agitation, and psychosis, though they are not primary psychotropic agents.

Adverse Effects

The adverse effect profiles are closely linked to the pharmacodynamic actions of each drug class.

Common Side Effects

Cholinesterase inhibitors commonly produce dose-related cholinergic side effects, particularly during dose escalation. These include gastrointestinal effects such as nausea, vomiting, diarrhea, anorexia, and weight loss. Other frequent effects are bradycardia, syncope, dizziness, insomnia, vivid dreams, and muscle cramps. The transdermal formulation of rivastigmine significantly reduces the incidence of gastrointestinal adverse events compared to the oral capsule. Memantine is generally well-tolerated. The most commonly reported side effects are dizziness, headache, confusion, constipation, and somnolence. These are often transient and mild to moderate in severity.

The monoclonal antibodies are associated with unique adverse events related to their mechanism. Amyloid-related imaging abnormalities (ARIA) are the most significant concern. ARIA is detected on MRI as either edema/effusion (ARIA-E) or microhemorrhages and superficial siderosis (ARIA-H). These events are often asymptomatic but can present with headache, confusion, dizziness, vision changes, or nausea. Other infusion-related reactions, including flu-like symptoms, may occur.

Serious/Rare Adverse Reactions

Serious adverse effects of cholinesterase inhibitors include symptomatic bradycardia leading to syncope or falls, heart block, and exacerbation of asthma or chronic obstructive pulmonary disease due to increased bronchial secretions. Rare cases of seizures and neuroleptic malignant syndrome-like reactions have been reported. For memantine, rare but serious effects include severe dizziness, psychosis, and heart failure. The most serious risk associated with amyloid-targeting monoclonal antibodies is symptomatic ARIA, which can, in rare instances, lead to seizures, severe neurological deficits, or hospitalization. The risk is higher in carriers of the apolipoprotein E ε4 allele.

Black Box Warnings

Currently, none of the traditional cholinesterase inhibitors or memantine carry FDA-mandated black box warnings. However, the monoclonal antibodies aducanumab and lecanemab have a black box warning regarding the risk of ARIA. This warning mandates that prescribing be limited to physicians with experience in managing Alzheimer’s disease, emphasizes the need for baseline MRI and periodic monitoring, and instructs on dosage suspension or discontinuation in cases of symptomatic ARIA.

Drug Interactions

Potential drug interactions are a critical consideration, particularly in elderly patients who are likely to be on multiple medications for comorbid conditions.

Major Drug-Drug Interactions

Cholinesterase inhibitors have several important interactions. Pharmacodynamic interactions with other cholinergic agents (e.g., bethanechol, succinylcholine) can lead to excessive cholinergic stimulation. Concurrent use with anticholinergic medications (e.g., oxybutynin, tricyclic antidepressants, first-generation antihistamines) can antagonize the therapeutic effect. Donepezil and galantamine, as substrates of CYP2D6 and CYP3A4, may have their plasma concentrations altered by strong inhibitors (e.g., paroxetine, ketoconazole) or inducers (e.g., carbamazepine, rifampin) of these enzymes. Rivastigmine, with minimal CYP metabolism, has fewer pharmacokinetic interactions. Cholinesterase inhibitors may potentiate the bradycardic effects of beta-blockers and non-dihydropyridine calcium channel blockers like diltiazem and verapamil.

Memantine, being renally excreted unchanged, has few pharmacokinetic interactions. However, drugs that alkalinize the urine (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) can reduce its renal clearance by decreasing tubular secretion, potentially increasing plasma levels. Pharmacodynamic interactions with other NMDA antagonists (e.g., amantadine, ketamine, dextromethorphan) could theoretically increase the risk of neuropsychiatric effects, though clinical significance is uncertain.

For monoclonal antibodies, no classic pharmacokinetic drug interactions are expected due to their distinct elimination pathway. However, concomitant use of anticoagulant or antiplatelet therapy may theoretically increase the risk of serious hemorrhage in the context of ARIA-H.

Contraindications

Absolute contraindications for cholinesterase inhibitors include known hypersensitivity to the drug or its components and patients with severe liver disease. They are relatively contraindicated in patients with a history of severe cardiac conduction disorders (e.g., sick sinus syndrome, high-grade atrioventricular block), active peptic ulcer disease, severe asthma, or chronic obstructive pulmonary disease. Memantine is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) due to significant renal excretion. The monoclonal antibodies are contraindicated in patients with a history of serious hypersensitivity to the drug and, importantly, in patients for whom MRI is contraindicated (e.g., those with certain implanted devices or severe claustrophobia), given the mandatory requirement for monitoring.

Special Considerations

The use of Alzheimer’s medications requires careful adjustment and monitoring in specific patient populations.

Use in Pregnancy and Lactation

Alzheimer’s disease is exceedingly rare in women of childbearing potential. Therefore, clinical data on the use of these agents during pregnancy and lactation are extremely limited. Cholinesterase inhibitors and memantine are classified as Pregnancy Category C (US FDA) or have not been assigned a formal category in more recent systems, indicating that animal reproduction studies have shown adverse effects, and there are no adequate, well-controlled studies in humans. Their use during pregnancy is not indicated. It is not known whether these drugs are excreted in human milk. Given the potential for serious adverse reactions in nursing infants, a decision must be made to discontinue nursing or discontinue the drug.

Pediatric and Geriatric Considerations

These medications are not indicated for pediatric use. The geriatric population is the primary treatment group. Age-related physiological changes significantly impact pharmacokinetics. Reduced hepatic mass and blood flow, as well as potential declines in cytochrome P450 activity (particularly CYP2D6), can reduce the clearance of drugs like donepezil and galantamine, potentially increasing exposure. Age-related decline in renal function is a paramount consideration for memantine, necessitating dose adjustment based on creatinine clearance. The increased prevalence of polypharmacy, multimorbidity, and frailty in the elderly heightens the risk of drug interactions and adverse events like falls, bradycardia, and gastrointestinal intolerance. Slow titration and vigilant monitoring are essential.

Renal and Hepatic Impairment

Dosage adjustment for renal impairment is crucial for memantine. In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), a target dose reduction is recommended. It is not recommended for patients with severe impairment (creatinine clearance less than 30 mL/min). Cholinesterase inhibitors generally do not require renal dose adjustment, as they are not primarily renally eliminated.

For hepatic impairment, caution is advised with all cholinesterase inhibitors. Donepezil and galantamine, being metabolized hepatically, may have reduced clearance in patients with significant liver disease, warranting careful titration and possibly lower maintenance doses. Rivastigmine, with minimal hepatic metabolism, may be preferred in such cases, though it is still contraindicated in severe liver impairment. Memantine does not require hepatic dose adjustment. The monoclonal antibodies have not been formally studied in significant hepatic impairment, but due to their catabolic clearance, major dose adjustments are not anticipated.

Summary/Key Points

• The pharmacological management of Alzheimer’s disease currently relies on two main symptomatic classes: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild to moderate disease and the NMDA receptor antagonist memantine for moderate to severe disease. Combination therapy is common in later stages.
• The primary mechanism of cholinesterase inhibitors is to increase synaptic acetylcholine levels, countering cholinergic deficit. Memantine modulates pathological glutamatergic signaling to reduce excitotoxicity. Emerging monoclonal antibodies (aducanumab, lecanemab, donanemab) target amyloid-beta plaques with the goal of disease modification in early-stage, amyloid-positive patients.
• Pharmacokinetic profiles vary widely, influencing dosing strategies. Key considerations include the long half-life of donepezil, the alternative transdermal route for rivastigmine, the renal excretion of memantine requiring dose adjustment in impairment, and the intravenous, extended-interval dosing of monoclonal antibodies.
• Adverse effects are often mechanism-based: cholinergic gastrointestinal and cardiac effects for ChEIs; dizziness and confusion for memantine; and amyloid-related imaging abnormalities (ARIA) for monoclonal antibodies, necessitating MRI surveillance.
• Significant drug interactions include pharmacodynamic antagonism with anticholinergics for ChEIs, CYP-based interactions for donepezil and galantamine, and urine pH effects on memantine clearance. Use in geriatric patients demands careful titration and monitoring for polypharmacy and comorbidity-related risks.

Clinical Pearls

• Always initiate cholinesterase inhibitors at a low dose and titrate slowly over several weeks to improve gastrointestinal tolerability. The transdermal patch formulation of rivastigmine offers a favorable side effect profile.
• In patients with significant bradycardia or conduction disease, or those on multiple bradycardic agents, the risk-benefit ratio of cholinesterase inhibitors must be carefully evaluated, and cardiac monitoring may be warranted.
• For memantine, estimate renal function using the Cockcroft-Gault equation and adjust the dose accordingly to prevent accumulation and toxicity.
• Prescribing amyloid-targeting monoclonal antibodies requires confirmation of amyloid pathology, baseline MRI, APOE ε4 genotyping to inform ARIA risk, and commitment to regular monitoring MRIs. Treatment should be managed by specialists familiar with these protocols.
• Therapeutic expectations should be clearly communicated to patients and caregivers: current symptomatic treatments offer modest slowing of decline, not improvement or cure, while disease-modifying therapies aim to slow progression in early disease.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.